Drug development company NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) is not ready to give up on EmtinB, its trademark drug that didn’t make it past the Human Research Ethics Committee (HREC) and resulted in the Company’s previous CEO resigning. Remaining undeterred, it has filed a new patent, entitled “Neuroprotective compositions and methods”, that will use a
Read More
After the Human Research Ethics Committee (HREC) rejected the Company’s flagship drug, EmtinB, knocking back years of research in the process, disappointed CEO and Managing Director, Mr Matt Liddelow, announced that he is resigning from his position immediately. Liddelow noted, “I acknowledge the loss in shareholder value as a result of the rejected Human Research
Read More
Aussies suffering from Alzheimer’s disease may have avoided some sketchy science after drug development company Neuroscientific Biopharmaceuticals (ASX: NSB) had their application to commence Phase 1 trials in humans, rejected by the Human Research Ethics Committee (HREC). In order for any drug development company to commence trials in humans, they must secure HREC approvals which
Read More
The 60 million individuals around the world who suffer from glaucoma could one day have a cure for the debilitating eye disease from NeuroScientific Biopharmaceuticals (ASX: NSB), with the company buoyed by initial results from their preclinical trials. The drug development company’s lead product, EmtinB – a therapeutic peptide which has had positive results for
Read More
With the average person’s life expectancy rising, Alzheimer’s disease is emerging as a major health concern which can have devastating effects on an individual’s cognitive function. It leads to progressive loss of brain cells which later leads to loss of memory and has become a global menace, costing the world over US$818 billion in treatment
Read More